glp 1 in virginia West residents struggle to afford GLP-1 weight loss drugs after state ends subsidy program Weight-loss drugs are booming in

Patients with severe kidney disease (eGFR below 15 mL/min/1.73m) require special monitoring, though mild-to-moderate kidney impairment is not a contraindication to GLP-1 use

Funding This work was supported by grants from the Natural Science Foundation of Guangdong Province (2018A030313846 and 2021A1515012593), the Science and Technology Planning Project of Guangdong Province (2019A030317020), the National Natural Science Foundation of China (81802257, 81871859, 81772457, 82172750, 82172811, and 82260546), the Guangdong Basic and Applied Basic Research Foundation (GuangdongGuangzhou Joint Funds) (2022A1515111212), and the Science and Technology Program of Guangzhou (2023A04J1257)

Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials

Some demand documentation of failed prior weight loss attempts, including supervised diet programs or other medications like phentermine , before approving GLP-1 coverage regardless of BMI